Growth hormone deficiency: Strategies and indications to continue growth hormone therapy in transition from adolescence to adult life

Hormone Research

Volumn 60, Issue SUPPL. 1, 2003, Pages 78-85

  Leong, Gary M ^a   Johannsson, Gudmundur ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adolescence; Bone; Discontinuation; Growth hormone; Growth hormone deficiency; Metabolism; Quality of life; Retesting; Transition

Indexed keywords

RECOMBINANT GROWTH HORMONE;

ADOLESCENCE; ADOLESCENT; ADULT; ADULTHOOD; BODY HEIGHT; BONE MATURATION; BRAIN CANCER; CANCER RECURRENCE; CANCER THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; LONG TERM CARE; MUSCLE DEVELOPMENT; MUSCLE STRENGTH; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE OF ONSET; BODY HEIGHT; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS;

EID: 0041411665     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071231     Document Type: Conference Paper

References (57)

1. Borges O: Isometric and isokinetic knee extension and flexion torque in men and women aged 20-70. Scand J Rehab Med 1989;21:45-53.
2. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB: Bone gain in young adult women. JAMA 1992;268:2403-2408.
3. Rosen T, Bengtsson BA: Premature mortality due to cardiovascular diseases in hypopituitarism. Lancet 1990;336:285-288.
4. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.
5. Bengtsson BA, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L, Isaksson OG: Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993;76:309-317.
6. Salomon F, Cuneo RC, Hesp R, Sonksen PH: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989;321:1797-1803.
7. Rosen T, Wiren L, Wilhelmsen L, Wiklund I, Bengtsson BA: Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol 1994;40:111-116.
8. Bengtsson BA, Johannsson G: Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults. Lancet 1999; 353:1898-1899.
9. Jorgensen JO, Pedersen SA, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS: Beneficial effect of growth hormone treatment in GH-deficient adults. Lancet 1989;i:1221-1225.
10. De Boer H, Blok GJ, Voerman HJ, De Vries PMJ, Van Der Veen EA: Body composition in adult growth hormone-deficient men, assessed by anthropodometry and bioimpedance analysis. J Clin Endocrinol Metab 1992;75:833-837.
11. Attanasio AF, Lamberts SW, Matranga AM, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson BA, Strasburger CJ: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997; 82:82-88.
12. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA: Two years of growth hormone (GH) treatment increases isometric and isoki-netic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997;82:2877-2884.
13. Kaufman JM, Taelman P, Vermeulen A, Vandeweghe M: Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992;74:118-123.
14. Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson BA: Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993;129:201-208.
15. Cittadini A, Cuocolo A, Merola B, Fazio S, Sabatini D, Nicolai E, Colao A, Longobardi S, Lombardi G, Sacca L: Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 1994;267:E219-E225.
16. Longobardi S, Cuocolo A, Merola B, Di Rella F, Colao A, Nicolai E, Cardei S, Salvatore M, Lombardi G: Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol (Oxf) 1998;48:137-143.
17. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rosen T, Thoren M, Bengtsson BA: The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH binding protein, body mass index, age and gender. J Clin Endocrinol Me-tab 1996;81:1575-1581.
18. Janssen YJ, Frolich M, Roelfsema F: A low starting dose of genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 1997;82:129-135.
19. Saggese G, Baroncelli GI, Bertelloni S, Barsanti S: The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996;81:3077-3083.
20. Attanasio AF, Howell S, Bates PC, Frewer P, Chipman J, Blum WF, Shalet SM: Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab 2002;87:3368-3372.
21. Koranyi J, Svensson J, Gotherstrom G, Sunnerhagen KS, Bengtsson B, Johannsson G: Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood and adult onset: a comparative, prospective study. J Clin Endo-crinol Metab 2001;86:4693-4699.
22. Rutherford OM, Jones DA, Round JM, Buchanan CR, Preece MA: Changes in skeletal muscle and body composition after discontination of growth hormone treatment in growth hormone deficient adults. Clin Endocrinol (Oxf) 1991;34:469-475.
23. Colle M, Auzerie J: Discontinuing of growth hormone therapy in growth-hormone-deficient patients: assessment of body fat mass using bioelectrical impedance. Horm Res 1993;39: 192-196.
24. Ogle GD, Moore B, Lu PW, Craighead A, Briody JN, Cowell CT: Changes in body composition and bone density after discontinuation of growth hormone therapy in adolescence: an interim report. Acta Peadiatr 1994;399(suppl): 3-7.
25. Johannsson G, Albertsson-Wikland K, Bengtsson BA: Discontinuation of growth hormone (GH) treatment: Metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999;84: 4516-4524.
26. Porkka KV, Viikari JS, Taimela S, Dahl M, Akerblom HK: Age and gender specific serum lipid and apolipoprotein fractiles of Finnish children and young adults. The Cardiovascular Risk in Young Finns Study. Acta Paediatr 1994;83:838-848.
27. Ogle GD, Allen JR, Humphries IR, Lu PW, Briody JN, Morley K, Howman-Giles R, Cowell CT: Body-composition assessment by dual-energy x-ray absorptiometry in subjects aged 4-26 y. Am J Clin Nutr 1995;61:746-753.
28. Norrelund H, Vahl N, Juul A, Moller N, Alberti KG, Skakkebaek NE, Christiansen JS, Jorgensen JO: Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood and adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab 2000;85:1874-1881.
29. Norrelund H, Vahl N, Juul A, Moller N, Alberti KG, Skakkebaek NE, Christiansen JS, Jorgensen JO: Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism. J Clin Endocrinol Metab 2000;85:1912-1917.
30. Hulthen L, Bengtsson BA, Sunnerhagen KS, Hallberg L, Grimby G, Johannsson G: GH is needed for the maturation of muscle mass and strength in adolescents. J Clin Endocrinol Metab 2001;86:4765-4770.
31. Colao A, Di Somma C, Spinelli L, Orio F, Lombardi G: The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002;87:3650-3655.
32. Fors H, Bjarnason R, Wiren L, Albertsson-Wikland K, Bosaeus L, Bengtsson BA, Jo-hannsson G: Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents. Clin Endocrinol (Oxf) 2001;55:617-624.
33. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM: Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Clin Endocrinol (Oxf) 1995;42: 3-7.
34. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Shaw NJ, Camacho-Hubner C, Dunger DB, Chetham TD, Savage MO, Monson JP: Arrested bone mineralisation in GHD adolescents at final height. Growth Hormone IGF Res 2002;12:Abstract 018.
35. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G: A prospective investigation of quality of life and psychological well-being following the discontinuation of growth hormone (GH) treatment in adolescent patients who had GH deficiency during their childhood. J Clin Endocrinol Metab 2001;86:3494-3498.
36. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Smethurst LE, Shalet SM: Influences on quality of life in GH deficient adults and their effect on response to treatment. Clin Endocrinol (Oxf) 1999;51:565-573.
37. Sizonenko PC, Clayton PE, Cohen P, Hintz RL, Tanaka T, Laron Z: Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: Diagnosis of growth hormone deficiency. Growth Hormone IGF Res 2001;11:137-165.
38. Hoffman DM, Nguyen TV, O'Sullivan AJ, Baxter RC, Ho KK: Diagnosis of growth hormone deficiency in adults. Lancet 1994;343:1064-1068.
39. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83:379-381.
40. Aimaretti G, Baffoni C, Bellone S, Di Vito L, Corneli G, Arvat E, Benso L, Camanni F, Ghigo E: Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. J Clin Endocrinol Metab 2000;85:3693-3699.
41. Longobardi S, Merola B, Pivonello R, Di Rella F, Di Somma C, Colao A, Ghigo E, Camanni F, Lombardi G: Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J Clin Endocrinol Metab 1996;81:1244-1247.
42. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ: Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002;87:477-485.
43. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH Research Society. J Clin Endocrinol Metab 2000;85:3990-3993.
44. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML: Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 2002;87:2067-2079.
45. Nicolson A, Toogood AA, Rahim A, Shalet SM: The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol (Oxf) 1996;44:311-316.
46. Transition of GH-deficient patients from paediatric to adult endocrine care. International Growth Monitor 2001;12:29.
47. Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86:1868-1870.
48. Lawson Wilkins Pediatric Endocrine Society (LWPES) Writing Committee: Growth hormone treatment and neoplasia - coincidence or consequence? J Clin Endocrinol Metab 2002; 87:5351-5352.
49. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WD, Brada M, Hayward RD, Brook CG, Hindmarsh PC, Shalet SM: Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000;85:4444-4449.
50. Swerdlow AJ, Higgins CD, Adlard P, Preece MA: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: A cohort study. Lancet 2002;360: 273-277.
51. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J: Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clin Endocrinol (Oxf) 1998;49:441-445.
52. Nilsson B, Gustavsson-Kadaka E, Bengtsson BA, Jonsson B: Pituitary adenomas in Sweden between 1958 and 1991: Incidence, survival, and mortality. J Clin Endocrinol Metab 2000; 85:1420-1425.
53. Cutfield WS, Wilton P, Bennmarker H, Albertsson-Wikland K, Chatelain P, Ranke MB, Price DA: Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 2000;355:610-613.
54. Fowelin J, Attvall S, Lager I, Bengtsson BA: Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993;42:1443-1447.
55. Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson BA, Johannsson G: A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001;86:4657-4665.
56. Johannsson G, Rosen T, Bengtsson BA: Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997;47:571-581.
57. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP: Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998;83:3913-3919.